Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

Summary

The purpose of this phase I/II study is to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve patients with stage IV metastatic pancreatic carcinoma.

General Information

NCT#: NCT03310632
Study ID: GHPanc-1-001
Trial Phase: Phase I/II

Trial Sponsor: Golden Biotechnology Corporation, Covance
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Antroquinonol

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search